| http://www.w3.org/ns/prov#value | - The concurrent administration of TNFR:Fc together with RANK:Fc or osteoprotegerin is useful for preventing bone destruction in various settings including but not limited to osteoporosis, multiple myeloma or other malignancies that cause bone degeneration, or anti-tumor therapy aimed at preventing metastasis to bone, or bone destruction associated with prosthesis wear debris or with periodontitis.
|
